Big drug companies and biotech firms are working overtime on therapies and vaccines aimed at stopping COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2 At the same time, these companies are struggling, amid social distancing and the diversion of clinical resources, to keep clinical trials going for the rest of their therapeutic pipelines Eli Lilly and Company’s stated strategy is typical of big pharma The firm says it will delay the start of most new studies and pause enrollment in most ongoing ones Lilly will continue clinical trials for people who are already enrolled “By delaying most new study starts and pausing enrollment of new patients or healthy volunteers in most ongoing studies, we hope to ease the burden on participating healthcare facilities and allow physicians to focus more of their efforts on combatting COVID-19,” Tim Garnett, Lilly’s chief medical officer, says in a statement “We will maintain ongoing